/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel dual agonist leads to notable IOP lowering

    Safety, tolerability reasonable for new medication regardless of a.m. or p.m. dosing

    Take-home: The drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.

    Philadelphia—In a group of 123 patients, the drug ONO-9054 showed a greater reduction in IOP and a longer duration of IOP reduction compared with latanoprost (Xalatan, Pfizer), said Eydie G. Miller-Ellis, MD.

    ONO-9054 is a highly selective and potent dual EP3 and FP prostanoid receptor agonist.

    More: Cataract surgery may benefit these PAC/PACG patients

    “It’s hypothesized that agonist activity against EP3 and FP receptors might provide more sustained reduction in IOP than the FP agonist latanoprost,” said Dr. Miller-Ellis, chief, glaucoma service, and professor of clinical ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

    Two previous clinical trials have shown that ONO-9054 both increases uveoscleral and trabecular outflow in animals and that it is safe and well tolerated in healthy normotensive adults and subjects with open-angle glaucoma (OAG) and ocular hypertension.

    Related: What astronauts can teach us about glaucoma

    The previous research has found IOP reductions both from single and repeated doses. The IOP reductions extended to 33 hours post-dose.

    “There are clinically relevant reductions in IOP regardless of a.m. or p.m. dosing,” Dr. Miller-Ellis said.

    Comparator study

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results